Private Market View

Zhennuo Pharmaceuticals

Tianjin, China · Founded 2022 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
Last round

Key facts

  • Notable investors include Tianjin Binhai Industrial Fund Management.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 1 names
  • ·Watchlist + deal alerts for Zhennuo Pharmaceuticals
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Zhennuo Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Zhennuo Pharmaceuticals

Manufacturer of active pharmaceutical ingredients designed to support drug discovery and therapeutic development. The company offers high-purity antiviral intermediates and fluorinated fine chemicals, enabling pharmaceutical developers and healthcare providers to access reliable raw materials for effective drug manufacturing

Sector
Healthcare
HQ
Tianjin, China
Founded
2022
Ownership
Privately Held (backing)
PA Mark — not yet priced

Zhennuo Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Zhennuo Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Zhennuo Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.